Therefore, in order to obtain a PD treatment, the therapeutic applications of hWJ-MSCs and drug therapy, alone and in combination with each other, were evaluated by certain parameters such as motor disorders and dopaminergic neuronal count in SNc, and the levels of DA and TH in the striatum in a PD model. This evidence concerns the gene TH and Parkinson disease.